Heo, Sook-Kyoung Noh, Eui-Kyu Yoon, Dong-Joon Jo, Jae-Cheol Choi, Yunsuk Koh, SuJin Ho Baek, Jin Park, Jae-Hoo Joo Min, Young Kim, Hawk Radotinib induces CD11b<sup>+</sup>Annexin V<sup>+</sup> cells in BMCs from patients with AML. <p>Cells were incubated with various concentrations of radotinib for 72 h, harvested and immunostained with anti-human antibodies against CD11b and Annexin V. (A) The CD11b<sup>+</sup>Annexin V<sup>+</sup> cells in AML-1, AML-2 and AML-4. (B) Data show the fold-change of the number of CD11b<sup>+</sup>Annexin V<sup>+</sup> cells compared to control conditions in AML-1, AML-2, and AML-4. (C) The expression of Annexin V and CD11b in cells treated with 100 μM radotinib was monitored by FlowSight analysis (Patients: AML-1 and AML-4). Data represent the mean ± SEM. Statistically significant differences from the DMSO-treated control (*) are denoted as follows. **: <i>P</i> < 0.01; ***: <i>P</i> < 0.001. BF, bright field.</p> HL 60 cells;lyn;CD 11b cells;Acute Myeloid Leukemia Cells Radotinib;cml;CD 11b Cells Differentiated;tki;CD 11b HL 60 cells;radotinib;bcr;nb;atra;Radotinib Induces Apoptosis;Myeloid leukemia;CD 11b expression;thp;AML cells 2015-06-12
    https://plos.figshare.com/articles/figure/_Radotinib_induces_CD11b_Annexin_V_cells_in_BMCs_from_patients_with_AML_/1448466
10.1371/journal.pone.0129853.g005